血液透析
膜
替罗非班
透析
药物输送
透析管
血小板
医学
血小板活化
药品
化学
药理学
外科
内科学
有机化学
生物化学
经皮冠状动脉介入治疗
心肌梗塞
作者
Jiajing Tang,Dongmei Tong,Chuchu Tang,Shujing Wang,Guodong Dang,Weifeng Zhao,Shudong Sun,Changsheng Zhao
标识
DOI:10.1002/mabi.202400645
摘要
Abstract Thrombocytopenia is a potential complication associated with hemodialysis due to the unsatisfactory hemocompatibility of current dialysis membranes, which leads to excessive platelet destruction, accelerates organ failure, and threatens the patients’ life safety in severe cases. In the clinical application of hemodialysis, there are a proportion of patients suffer thrombocytopenia. For these patients, heparin combined with tirofiban can be used during dialysis to suppress the occurrence of thrombocytopenia, but the medication requires intravenous injection and continuous infusion. To optimize the application of hemodialysis membranes, a dialysis membrane composed of polyethersulfone (PES) base membrane and a temperature‐sensitive hydrogel coating poly ( N ‐acryloyl glycinamide) (PNAGA) is designed, and prepared that can continuously release tirofiban through temperature control to reduce the burden of medication on patients and significantly inhibit the occurrence of thrombocytopenia. The resulting membrane exhibits an encapsulation efficiency of 36.2% (72.4 µg mL −1 ) for tirofiban, with drug release rates of 54.83% at 37 °C and 31.4% at 4 °C after 1 h. Additionally, the membrane shows excellent hydrophilicity and dialysis performance. It also effectively inhibits platelet adhesion (reduced by 92.3%), activation (reduced by 92.8%) and aggregation, and albumin adsorption (reduced by 84.7%). In summary, the work provides a new solution for the preparation of dialysis membranes that can prevent thrombocytopenia, which has potential applications in the safer hemodialysis membrane manufacturing sector.
科研通智能强力驱动
Strongly Powered by AbleSci AI